106. クリオピリン関連周期熱症候群 Disease details / Clinical trials / Drug dev / DR info

ACZ885
   NOVARTIS FARMA
      2008   -   EUCTR2007-004367-22-IT   France;Germany;Italy;Spain;United Kingdom
   Novartis
      2008   Phase 3   NCT00685373   Belgium;France;Germany;India;Italy;Spain;Turkey;United Kingdom;United States
      2007   Phase 3   NCT00465985   France;Germany;India;Spain;United Kingdom;United States
   Novartis Farmacéutica S.A
      2012   -   EUCTR2011-005154-57-ES   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-ES   Belgium;France;Germany;Spain;United Kingdom
   Novartis Farmacéutica S.A.
      2008   -   EUCTR2007-004367-22-ES   Belgium;France;Germany;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005455-15-ES   France;Germany;Spain;United Kingdom
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2011-005154-57-GB   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2013   -   EUCTR2011-005154-57-FR   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2012   -   EUCTR2011-005154-57-DE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-005154-57-BE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016859-22-GB   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-DE   Belgium;France;Germany;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005455-15-GB   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005455-15-FR   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005455-15-DE   France;Germany;Spain;United Kingdom
      -   -   EUCTR2009-016859-22-Outside-EU/EEA   Canada;Israel;Switzerland
      -   Phase 3   EUCTR2009-016859-22-IE   Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom
      -   -   EUCTR2008-001429-32-Outside-EU/EEA   United States
      -   -   EUCTR2007-004367-22-Outside-EU/EEA   India;Turkey;United States
      -   -   EUCTR2006-005455-15-Outside-EU/EEA   India;United States
      -   -   EUCTR2004-002980-26-Outside-EU/EEA   India
   Novartis Pharmaceuticals
      2012   Phase 3   NCT01576367   Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom
      2010   Phase 3   NCT01302860   Belgium;Canada;France;Germany;Spain;Switzerland;United Kingdom
      -   -   EUCTR2015-003491-69-Outside-EU/EEA   Canada
      -   -   EUCTR2015-003490-15-Outside-EU/EEA   Japan
ACZ885 drug substance
   Novartis Pharma Services AG
      2007   -   EUCTR2004-002980-26-FR   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2004-002980-26-DE   France;Germany;Spain;United Kingdom
      2004   -   EUCTR2004-002980-26-GB   France;Germany;Spain;United Kingdom
Aidai score
   Hospices Civils de Lyon
      2024   -   NCT06544018   France
Anakinra
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2003   Phase 1/Phase 2   NCT00069329   United States
ANTI-interleukin-1B monoclonal antibody
   NOVARTIS FARMA
      2008   -   EUCTR2007-004367-22-IT   France;Germany;Italy;Spain;United Kingdom
ATI-450
   Aclaris Therapeutics, Inc.
      2020   Phase 2   NCT04524858   United States
Blood sampling
   Hospices Civils de Lyon
      2024   -   NCT06544018   France
C-028380
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom
Canakinumab
   Novartis
      2008   Phase 3   NCT00685373   Belgium;France;Germany;India;Italy;Spain;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A
      2012   -   EUCTR2011-005154-57-ES   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-ES   Belgium;France;Germany;Spain;United Kingdom
   Novartis Farmacéutica S.A.
      2008   -   EUCTR2007-004367-22-ES   Belgium;France;Germany;Italy;Spain;United Kingdom
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2011-005154-57-GB   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2013   -   EUCTR2011-005154-57-FR   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2012   -   EUCTR2011-005154-57-DE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-005154-57-BE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016859-22-GB   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-DE   Belgium;France;Germany;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom
      -   -   EUCTR2009-016859-22-Outside-EU/EEA   Canada;Israel;Switzerland
      -   Phase 3   EUCTR2009-016859-22-IE   Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom
      -   -   EUCTR2008-001429-32-Outside-EU/EEA   United States
      -   -   EUCTR2007-004367-22-Outside-EU/EEA   India;Turkey;United States
      -   -   EUCTR2006-005455-15-Outside-EU/EEA   India;United States
      -   -   EUCTR2004-002980-26-Outside-EU/EEA   India
   Novartis Pharmaceuticals
      2010   Phase 3   NCT01105507   Canada
      2009   Phase 3   NCT00991146   Japan
      2009   Phase 3   NCT00770601   United States
      -   -   EUCTR2015-003491-69-Outside-EU/EEA   Canada
      -   -   EUCTR2015-003490-15-Outside-EU/EEA   Japan
Canakinumab - proposed
   Novartis Farmacéutica S.A.
      2007   Phase 3   EUCTR2006-005455-15-ES   France;Germany;Spain;United Kingdom
   Novartis Pharma Services AG
      2007   Phase 3   EUCTR2006-005455-15-GB   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005455-15-FR   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005455-15-DE   France;Germany;Spain;United Kingdom
Circadian rhythm measurement
   Hospices Civils de Lyon
      2024   -   NCT06544018   France
DFV890
   NOVARTIS PHARMA AG
      2021   Phase 1;Phase 2   EUCTR2020-005948-33-IT   France;Germany;Italy;United States
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-005948-33-DE   France;Germany;Italy;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04868968   France;Germany;Italy;United Kingdom;United States
Genetic analysis OF NLRP3
   Hospices Civils de Lyon
      2024   -   NCT06544018   France
Ilaris
   Novartis Farmacéutica S.A
      2012   -   EUCTR2011-005154-57-ES   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
   Novartis Pharma Services AG
      2013   -   EUCTR2011-005154-57-FR   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2012   -   EUCTR2011-005154-57-DE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2012   Phase 3   EUCTR2011-005154-57-BE   Belgium;Canada;France;Germany;Israel;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-DE   Belgium;France;Germany;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom
      -   -   EUCTR2009-016859-22-Outside-EU/EEA   Canada;Israel;Switzerland
      -   Phase 3   EUCTR2009-016859-22-IE   Belgium;Canada;France;Germany;Ireland;Israel;Spain;Switzerland;United Kingdom
      -   -   EUCTR2008-001429-32-Outside-EU/EEA   United States
      -   -   EUCTR2007-004367-22-Outside-EU/EEA   India;Turkey;United States
      -   -   EUCTR2006-005455-15-Outside-EU/EEA   India;United States
      -   -   EUCTR2004-002980-26-Outside-EU/EEA   India
   Novartis Pharmaceuticals
      -   -   EUCTR2015-003491-69-Outside-EU/EEA   Canada
      -   -   EUCTR2015-003490-15-Outside-EU/EEA   Japan
   UZ Leuven
      2014   -   EUCTR2014-001393-34-BE   Belgium
Inzomelid
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom
IZD174
   Inflazome (Australia) Pty Ltd.
      2020   Phase 2   EUCTR2020-000489-40-GB   Australia;Ireland;United Kingdom
IZD334
   Inflazome UK Ltd
      2019   Phase 1   NCT04086602   Australia
Kineret
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      -   -   EUCTR2013-000300-42-Outside-EU/EEA   United States
Kineret*SC 7SIR 100MG 0,67ML
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy
Recombinant human monoclonal antibody TO human IL-1beta OF THE IGG1/K class
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2009-016859-22-FR   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-016859-22-GB   Belgium;France;Germany;Ireland;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-DE   Belgium;France;Germany;Spain;United Kingdom
      2010   -   EUCTR2009-016859-22-BE   Belgium;France;Germany;Spain;United Kingdom
      2009   -   EUCTR2007-004367-22-BE   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-004367-22-GB   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-FR   Belgium;France;Germany;Italy;Spain;United Kingdom
      2008   -   EUCTR2007-004367-22-DE   France;Germany;Italy;Spain;United Kingdom
Rilonacept
   Charite University, Berlin, Germany
      2009   Phase 2   NCT01045772   Germany
   Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy
      2008   -   EUCTR2006-004290-97-DE   Germany
Rilonacept 160 MG
   Regeneron Pharmaceuticals
      2005   Phase 3   NCT00288704   United States
Saliva sampling
   Hospices Civils de Lyon
      2024   -   NCT06544018   France
Tranilast
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03923140   China
VTX2735
   Zomagen Biosciences Ltd.
      2023   Phase 2   NCT05812781   United States
VX-765
   Vertex Pharmaceuticals Incorporated
      2004   Phase 2   EUCTR2004-000283-27-GB   United Kingdom
Xoma 052
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2010   Phase 1/Phase 2   NCT01211977   United States